Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Brown Lisle Cummings Inc.

Brown Lisle Cummings Inc. lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 2.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 22,692 shares of the medical research company’s stock after purchasing an additional 485 shares during the period. Amgen accounts for 2.2% of Brown Lisle Cummings Inc.’s portfolio, making the stock its 8th largest position. Brown Lisle Cummings Inc.’s holdings in Amgen were worth $7,312,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of the business. McClarren Financial Advisors Inc. grew its holdings in Amgen by 98.1% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 618 shares of the medical research company’s stock worth $199,000 after acquiring an additional 306 shares during the period. Cannon Financial Strategists Inc. grew its holdings in Amgen by 6.6% during the 3rd quarter. Cannon Financial Strategists Inc. now owns 1,200 shares of the medical research company’s stock worth $387,000 after acquiring an additional 74 shares during the period. Vest Financial LLC grew its holdings in Amgen by 2.9% during the 3rd quarter. Vest Financial LLC now owns 6,973 shares of the medical research company’s stock worth $2,247,000 after acquiring an additional 199 shares during the period. Nepsis Inc. grew its holdings in Amgen by 6.7% during the 3rd quarter. Nepsis Inc. now owns 59,715 shares of the medical research company’s stock worth $19,241,000 after acquiring an additional 3,735 shares during the period. Finally, Cyndeo Wealth Partners LLC grew its holdings in Amgen by 8.4% during the 3rd quarter. Cyndeo Wealth Partners LLC now owns 2,087 shares of the medical research company’s stock worth $673,000 after acquiring an additional 162 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on AMGN shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $362.00 target price on shares of Amgen in a report on Thursday, September 26th. Barclays boosted their price target on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a report on Monday, October 7th. Cantor Fitzgerald assumed coverage on shares of Amgen in a report on Friday, September 27th. They issued an “overweight” rating and a $405.00 price target for the company. Argus boosted their price target on shares of Amgen from $300.00 to $340.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Finally, Sanford C. Bernstein assumed coverage on shares of Amgen in a report on Thursday. They issued an “outperform” rating and a $380.00 price target for the company. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $332.45.

Amgen Stock Up 0.1 %

Amgen stock opened at $321.66 on Monday. The firm has a market capitalization of $172.55 billion, a PE ratio of 45.95, a P/E/G ratio of 2.86 and a beta of 0.61. The company’s 50-day moving average is $326.07 and its 200-day moving average is $312.41. Amgen Inc. has a fifty-two week low of $249.70 and a fifty-two week high of $346.85. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing the consensus estimate of $5.01 by ($0.04). The firm had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. Amgen had a return on equity of 161.72% and a net margin of 10.12%. The firm’s revenue for the quarter was up 20.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $5.00 earnings per share. Sell-side analysts anticipate that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were paid a $2.25 dividend. The ex-dividend date was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a yield of 2.80%. Amgen’s dividend payout ratio (DPR) is currently 128.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.